Just some valuation considerations to think about. Some

New Post Public Reply Private Reply Replies (1) Message Board
EliteYoda EliteYoda #444

Just some valuation considerations to think about.

Some have construed the fundamental valuation arguments to be so negative that I wanted to simply address the real numbers in a simple manner without spin, hype or bias. Some of the figures have been rounded to the nearest whole figure to provide a clearer picture.

O/S = 1 Billion shares 

P/E = ??

EPS = ??

PPS = P/E * EPS

The P/E multiple along with the EPS is a question mark because while the next quarters EPS is an unknown, the P/E is an ever changing value because the market for RFMK shares is so thin, individual buys and sells of a very small number of shares as compared to the total shares outstanding have dictated the daily price fluctuations which are therefore next to meaningless. All we can really assume is a range of possible P/E multiples placed on the stock based upon the multiples attributed to other similar stocks for companies with a similar growth path as RFMK. Lets assume that RFMK can grow annual earnings by double; effectively doubling their PROFITS each year, then the multiple could be as high as 100. If we assume they could grow earnings by say 50% then the P/E could be up to 50. I think we can assume with such a business plan as it is for RFMK, with their unique product, web and dispensary sales, connections and marketing strategy, the sales growth I should think would be at least 15% and probably higher. In most estimates of valuations it is usually wise to assume the middle of the road scenarios, so for RFMK we can assume 50% earnings growth per year, so we can use a P/E multiple of 50.

EPS is entirely unkown because once large sales are happening, it is difficult to know how good RFMKs margins will be, the overall costs incurred with bulk sales and logistics, as well as how large the initial market will be; how many customers will be buying the product in the first quarter. I think that we can assume margins should be quite good, because as was hinted by the CEO, the company can buy the units for $30, then if we assume an additional $20 for costs with the dispensaries cut included, then we can assume with a sales price of $100 that the company very simply makes $50 per unit in profits, which is a 50% margin, which is rather high. There are also P.I.R.D. repeat sales to factor in. However for simplicity I usually take the perspective that it is easier to just use such profits from that income stream to cover unexpected expenses over time, which leads to even more conservative estimates, which is always wise.

I think that if we assume revenues from consulting, PIRD sales, Bionic sales and all the other income streams besides the direct sales of the CannaCig are used to cover operating costs and expenditures then we can easily assume that the total profits should be $50 multiplied by the number of units which can be sold per quarter.

Now the calculations become much more simple because now the only question mark is how many CannaCigs do you think RFMK can sell each quarter? I think that if we assume we have about 10 dispensaries including OHM and Tabu and the webstore selling altogether as few as 100 units per day (that would be only about ten units per outlet per day) then in three months, 90 days, RFMK could make (100 * 90 * $50) = $450,000.

If we round that profit up to say $500k per quarter then annual profits would be four times that or $2M. Now, assuming these values and substituting we have,

EPS = $2M/1B = $0.002/share

P/E = 50

PPS = P/E * EPS = 50 * $0.002 = $0.10

Also if instead the year over year growth is $2M, if the collective selling power is 200 units per outlet per day, instead of only 100 units then P/E could be 100. In that case the PPS could soar to $0.20 !!!! Do your own DD, do your own fundamental valuation calculations and assumptions but this post is just me sharing my own personal perspectives and assumptions on the fundamentals and could be very very wrong. But I think that these assumptions are not completely out of left field and are actually quite conservative. I think the key metric to keep a close eye on is how many units can be sold once all outlets are selling with no inventory restrictions and full marketing campaign is in full swing and after at least one reported revenue quarter is in the books, THEN we will get an idea of the true demand out there and I think if we are pleasantly surprised with the demand, the stock could sky rocket with big investment coming in!

GLTA!

$RFMK!

Rapid Fire Marketing, Inc. (RFMK) Stock Research Links

RFMK Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Orbis Celebrates 20 Years of Eye Care in Macau

Updated Category News Views 2

Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...

Continue Reading
Ramaco Resources Faces Stock Shake-Up Amid Distribution

Updated Category News Views 0

Stock Shake-Up In The Coal Industry Something's brewing in the coal mines of West Virginia, and it isn't just the usual dust settling. Ramaco Resources, Inc. (NASDAQ: METC), the metallurgical coal titan, is feeling the heat from some unexpected stock market turbulence, and it's got everyone in the investment trenches scratching their heads. The Yorktown Energy Partners'...

Continue Reading
What to Expect from KeyCorp at Barclays Event

Updated Category News Views 4

KeyCorp's Next Move: An Insider's View Yep, circle that calendar, folks. Looks like KeyCorp's gonna be laying it all out there for the financial world to see. Clark Khayat, their numero uno money guy, is hitting the stage at the Barclays Global Financial Services Conference on Sept. 14. So grab the popcorn—or, more like, your portfolio tracker—because this could get...

Continue Reading
Charity's Bold Move: Acquiring Wayfinder for K-12 Impact

Updated Category News Views 1

Public Charity Expands Into Education Well, here's something that's bound to turn a few heads: a fast-growing public charity has just made its first acquisition in the K-12 sphere by snapping up Wayfinder. The stakes are getting interesting. When a charity starts playing in the acquisition space, you're looking at a change in strategy that deserves close attention. Why...

Continue Reading
YSL Beauty’s Block Party Series Rocks London's Scene

Updated Category News Views 3

YSL Beauty: More Than a Brand, a Cultural Movement London felt a distinct pulse this past weekend as YSL Beauty kicked off another sizzling event in its Block Party series. This one wasn't just another Instagrammable gathering; it was the kind of scene that shifted the cultural needle. What started in Madrid has now become a roving spectacle that sweeps across cities,...

Continue Reading
XTEND Launches on NYSE Amid Market Milestones

Updated Category News Views 2

XTEND Steps Into the NYSE Spotlight Out of the gate, let's talk about XTEND—a name that's about to make waves on the New York Stock Exchange. With their debut under the ticker XTND, these folks are slamming their flag into the financial terrain like a knight ready for battle. XTEND, an AI-powered defense robotics and software outfit, isn't just joining the party—it's...

Continue Reading
Argo Biopharma's BW-20805 Shows Promise in HAE Phase II Trial

Updated Category News Views 1

Argo's Gains in Hereditary Angioedema Therapy Think about it, folks – reducing a hereditary angioedema attack by over 80%? Argo Biopharma, the slick operator in the RNA therapeutics space, is flexing its muscles again. They've hauled in some impressive data for their siRNA therapeutic, BW-20805, at the 2026 Bradykinin Symposium in Berlin. For you deep-pocketed investors...

Continue Reading
Ed Markey's Political Future on Shaky Ground in MA

Updated Category News Views 2

Massachusetts Voters Voice Desire for Change Ever seen an old engine stutter and cough before finally quitting? That's what Ed Markey's political career is starting to feel like. A fresh poll has surfaced, casting doubt over his steady grip on his longstanding Senate seat in Massachusetts. People are yearning for fresh faces and new ideas like never before. It's as if the...

Continue Reading
Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Updated Category News Views 4

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Continue Reading
Parents Champion Meta's Online Safety Agreement

Updated Category News Views 3

Any old-timer in the market game will tell you this: safeguarding the next generation runs deeper than just chasing profits. A recent poll by the Coalition to Empower our Future reveals something that ain’t too surprising if you’ve been paying attention. Parents all over the nation are nodding along to Meta’s new move to bolster online protections for younger folks....

Continue Reading

Top 5 Most Recently Viewed Articles

Hedge Fund Strategies: Insights for 2025 Market Dynamics

Updated Category News Views 2154

The Shifting Landscape of Hedge Fund Investments for 2025 As we navigate toward 2025, hedge fund investors are increasingly drawn to macro strategies, reflecting a transformative phase in the financial markets. This trend is largely driven by the evolving political landscapes and their potential impacts on economic conditions globally. Investors are strategically...

Continue Reading
EHang Secures Over $22 Million Investment from Enpower and Others

Updated Category News Views 128

EHang's Strategic Investment Boosts Urban Air Mobility Growth GUANGZHOU, China - EHang Holdings Limited (Nasdaq: EH), renowned for its leadership in Urban Air Mobility (UAM), has recently announced a significant strategic investment exceeding US$22 million. This investment is spearheaded by Zhuhai Enpower Electric Co., Ltd., a leading provider of power systems for new...

Continue Reading
e.l.f. Beauty, Inc. Class Action: Understand Your Rights

Updated Category News Views 123

e.l.f. Beauty, Inc. Class Action Overview Attention investors! A class action lawsuit has been filed against e.l.f. Beauty, Inc. This important case involves investors who purchased shares of this makeup brand during a specific time frame and may have experienced financial losses due to misleading information. Details of the Class Action Case e.l.f. Beauty, known for its...

Continue Reading
CareCloud Set to Lead AI Healthcare Discussion at Tech Event

Updated Category News Views 109

CareCloud to Showcase AI Innovations at Upcoming Tech Conference CareCloud, Inc. (Nasdaq: CCLD, CCLDO), known for its pioneering role in AI-driven healthcare technology solutions, is gearing up to take center stage at the upcoming virtual tech conference presented by Maxim Group LLC. This exciting event will feature an enlightening Healthcare IT Panel on June 3, where...

Continue Reading
Understanding Accenture's Short Interest Trends and Impacts

Updated Category News Views 216

Understanding Accenture's Short Interest Trends Accenture's short percent of float has notably dropped by 4.0% since its previous report. Currently, the company has approximately 6.03 million shares sold short, representing about 0.96% of all available regular shares for trading. This figure indicates that, with current trading volume, traders would require an estimated...

Continue Reading